Jennison Associates’s Integra LifeSciences IART Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-42,841
| Closed | -$614K | – | 609 |
|
|
2025
Q3 | $614K | Buy |
+42,841
| New | +$587K | ﹤0.01% | 517 |
|
|
2024
Q2 | – | Sell |
-181,299
| Closed | -$6.43M | – | 589 |
|
|
2024
Q1 | $6.43M | Buy |
181,299
+8,382
| +5% | +$335K | ﹤0.01% | 421 |
|
|
2023
Q4 | $7.53M | Sell |
172,917
-14,414
| -8% | -$567K | 0.01% | 409 |
|
|
2023
Q3 | $7.15M | Sell |
187,331
-179,513
| -49% | -$7.55M | 0.01% | 393 |
|
|
2023
Q2 | $15.1M | Buy |
366,844
+6,758
| +2% | +$325K | 0.01% | 350 |
|
|
2023
Q1 | $20.7M | Buy |
360,086
+771
| +0.2% | +$43.4K | 0.02% | 323 |
|
|
2022
Q4 | $20.1M | Buy |
359,315
+18,950
| +6% | +$965K | 0.02% | 323 |
|
|
2022
Q3 | $14.4M | Buy |
340,365
+64,963
| +24% | +$3.33M | 0.01% | 360 |
|
|
2022
Q2 | $14.9M | Buy |
275,402
+69,315
| +34% | +$4.16M | 0.01% | 346 |
|
|
2022
Q1 | $13.2M | Sell |
206,087
-1,242
| -0.6% | -$81.8K | 0.01% | 393 |
|
|
2021
Q4 | $13.9M | Buy |
207,329
+57,364
| +38% | +$3.88M | 0.01% | 414 |
|
|
2021
Q3 | $10.3M | Sell |
149,965
-172,545
| -54% | -$12.2M | 0.01% | 450 |
|
|
2021
Q2 | $22M | Sell |
322,510
-69,293
| -18% | -$4.9M | 0.01% | 358 |
|
|
2021
Q1 | $27.1M | Sell |
391,803
-14,315
| -4% | -$970K | 0.02% | 314 |
|
|
2020
Q4 | $26.4M | Buy |
406,118
+48,322
| +14% | +$2.6M | 0.02% | 306 |
|
|
2020
Q3 | $16.9M | Sell |
357,796
-115,307
| -24% | -$5.48M | 0.01% | 321 |
|
|
2020
Q2 | $22.2M | Sell |
473,103
-197,181
| -29% | -$9.69M | 0.02% | 280 |
|
|
2020
Q1 | $29.9M | Sell |
670,284
-120,394
| -15% | -$6.32M | 0.04% | 202 |
|
|
2019
Q4 | $46.1M | Buy |
790,678
+57,994
| +8% | +$3.45M | 0.05% | 195 |
|
|
2019
Q3 | $44M | Sell |
732,684
-90,502
| -11% | -$5.39M | 0.05% | 202 |
|
|
2019
Q2 | $46M | Buy |
823,186
+31,582
| +4% | +$1.63M | 0.05% | 218 |
|
|
2019
Q1 | $44.1M | Sell |
791,604
-68,333
| -8% | -$3.48M | 0.04% | 247 |
|
|
2018
Q4 | $38.8M | Sell |
859,937
-151,518
| -15% | -$8.31M | 0.04% | 249 |
|
|
2018
Q3 | $66.6M | Sell |
1,011,455
-3,247
| -0.3% | -$202K | 0.06% | 209 |
|
|
2018
Q2 | $65.4M | Sell |
1,014,702
-141,648
| -12% | -$8.77M | 0.06% | 220 |
|
|
2018
Q1 | $64M | Buy |
1,156,350
+140,045
| +14% | +$7.34M | 0.06% | 222 |
|
|
2017
Q4 | $48.6M | Sell |
1,016,305
-18,397
| -2% | -$900K | 0.05% | 266 |
|
|
2017
Q3 | $52.2M | Buy |
1,034,702
+336,930
| +48% | +$17.3M | 0.05% | 262 |
|
|
2017
Q2 | $38M | Buy |
697,772
+76,548
| +12% | +$3.66M | 0.04% | 308 |
|
|
2017
Q1 | $26.2M | Buy |
+621,224
| New | +$26.5M | 0.03% | 383 |
|
Other funds holding IART
RCMNY
PCMI
Jennison Associates's IART Position: Q4 2025 in Review
Jennison Associates sold out of Integra LifeSciences (IART) in Q4 2025, closing a stake of 42,841 shares — an estimated $614K sold.
Jennison Associates first reported a position in IART in Q1 2017 and held it in 30 quarters. The position peaked at $66.6M in Q3 2018. 204 funds tracked by Wall St. Rank hold IART as of Q4 2025.
- Jennison Associates reported no remaining Integra LifeSciences position as of Q4 2025 after selling out during the quarter.
- Jennison Associates sold 42,841 Integra LifeSciences shares in Q4 2025, an estimated $614K.
- Jennison Associates first reported a position in Integra LifeSciences in Q1 2017 and held it in 30 quarters.
- Jennison Associates's Integra LifeSciences position peaked at $66.6M in Q3 2018.
- 204 funds tracked by Wall St. Rank held Integra LifeSciences as of Q4 2025.
Based on Jennison Associates's 13F filing for Q4 2025, filed 30 Jan 2026.